Prognostic value of implantable defibrillator-computed respiratory disturbance index: The DASAP-HF study.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
03 2021
Historique:
received: 09 07 2020
revised: 01 10 2020
accepted: 22 10 2020
pubmed: 8 12 2020
medline: 21 12 2021
entrez: 7 12 2020
Statut: ppublish

Résumé

Sleep apnea, as measured by polysomnography, is associated with adverse outcomes in heart failure. The DASAP-HF (Diagnosis and Treatment of Sleep Apnea in Patient With Heart Failure) study previously demonstrated that the respiratory disturbance index (RDI) computed by the ApneaScan algorithm (Boston Scientific) accurately identifies severe sleep apnea in implantable cardioverter-defibrillator (ICD) patients. The purpose of the long-term study phase was to assess the incidence of clinical events after 24 months and investigate the association with RDI values. Patients with left ventricular ejection fraction ≤35% implanted with an ICD were enrolled and followed-up for 24 months. The RDI calculated at 1 month after implantation was used to stratify patients (below or above 30 episodes/h). The endpoints were all-cause death and a combination of all-cause death or cardiovascular hospitalization. Of the 265 enrolled patients, 224 had usable RDI values. Severe sleep apnea (RDI ≥30 episodes/h) was diagnosed in 115 patients (51%). These patients were more frequently male (84% vs 72%; P = .030) and had higher creatinine levels. During median follow-up of 25 months, 19 patients (8%) died. Cardiovascular hospitalizations were reported in 19 patients (8%). The risk of all-cause death was higher in patients with RDI ≥30 episodes/h (hazard ratio [HR] 3.33; 95% confidence interval [CI] 1.35-8.21; P = .023), as well as the risk of all-cause death or cardiovascular hospitalization (HR 1.94; 95% CI 1.01-3.76; P = .048). At multivariate analysis, independent predictors of death were RDI ≥30 episodes/h (HR 4.02; 95% CI 1.16-13.97; P = .029) and creatinine levels (HR 2.36; 95% CI 1.26-4.42; P = .008). In heart failure patients implanted with an ICD, higher RDI values are associated with death and cardiovascular hospitalizations. Device-detected severe sleep apnea independently predicts death.

Sections du résumé

BACKGROUND
Sleep apnea, as measured by polysomnography, is associated with adverse outcomes in heart failure. The DASAP-HF (Diagnosis and Treatment of Sleep Apnea in Patient With Heart Failure) study previously demonstrated that the respiratory disturbance index (RDI) computed by the ApneaScan algorithm (Boston Scientific) accurately identifies severe sleep apnea in implantable cardioverter-defibrillator (ICD) patients.
OBJECTIVE
The purpose of the long-term study phase was to assess the incidence of clinical events after 24 months and investigate the association with RDI values.
METHODS
Patients with left ventricular ejection fraction ≤35% implanted with an ICD were enrolled and followed-up for 24 months. The RDI calculated at 1 month after implantation was used to stratify patients (below or above 30 episodes/h). The endpoints were all-cause death and a combination of all-cause death or cardiovascular hospitalization.
RESULTS
Of the 265 enrolled patients, 224 had usable RDI values. Severe sleep apnea (RDI ≥30 episodes/h) was diagnosed in 115 patients (51%). These patients were more frequently male (84% vs 72%; P = .030) and had higher creatinine levels. During median follow-up of 25 months, 19 patients (8%) died. Cardiovascular hospitalizations were reported in 19 patients (8%). The risk of all-cause death was higher in patients with RDI ≥30 episodes/h (hazard ratio [HR] 3.33; 95% confidence interval [CI] 1.35-8.21; P = .023), as well as the risk of all-cause death or cardiovascular hospitalization (HR 1.94; 95% CI 1.01-3.76; P = .048). At multivariate analysis, independent predictors of death were RDI ≥30 episodes/h (HR 4.02; 95% CI 1.16-13.97; P = .029) and creatinine levels (HR 2.36; 95% CI 1.26-4.42; P = .008).
CONCLUSION
In heart failure patients implanted with an ICD, higher RDI values are associated with death and cardiovascular hospitalizations. Device-detected severe sleep apnea independently predicts death.

Identifiants

pubmed: 33283757
pii: S1547-5271(20)31030-4
doi: 10.1016/j.hrthm.2020.10.019
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02620930']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

374-381

Informations de copyright

Copyright © 2020 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Giuseppe Boriani (G)

University of Modena and Reggio Emilia, Modena, Italy. Electronic address: giuseppe.boriani@unimore.it.

Ennio C L Pisanò (ECL)

Vito Fazzi Hospital, Lecce, Italy.

Paolo Pieragnoli (P)

University of Florence, Florence, Italy.

Alessandro Locatelli (A)

"Bolognini" Hospital, Seriate (BG), Italy.

Alessandro Capucci (A)

Università Politecnica delle Marche, Ancona, Italy.

Antonello Talarico (A)

Ospedale SS. Annunziata, Cosenza, Italy.

Massimo Zecchin (M)

University of Trieste, Trieste, Italy.

Antonio Rapacciuolo (A)

Federico II University, Naples, Italy.

Marcello Piacenti (M)

Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Ciro Indolfi (C)

"Magna Graecia" University, Catanzaro, Italy.

Miguel Angel Arias (MA)

Hospital Virgen de la Salud, Toledo, Spain.

Igor Diemberger (I)

University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy.

Catia Checchinato (C)

Ospedale Santa Croce, Moncalieri (TO), Italy.

Maria Teresa La Rovere (MT)

Istituti Clinici Scientifici Maugeri, IRCCS, Istituto Scientifico di Montescano, Montescano, Pavia.

Gianfranco Sinagra (G)

University of Trieste, Trieste, Italy.

Michele Emdin (M)

Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Renato Pietro Ricci (RP)

Italian Heart Rhythm Society (AIAC), Rome, Italy.

Antonio D'Onofrio (A)

Ospedale Monaldi, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH